zafirlukast

Zafirlukast (ICI 204219) is an orally active leukotriene D4 receptor (LTD4) antagonist (IC50=0.6 μM). Zafirlukast has anti-asthmatic, anti-inflammatory, and antimicrobial properties and is used in the prevention and treatment of asthma.

Zafirlukast metabolite M1 (compound 15) is an inhibitor used in the treatment of asthma and other allergic pulmonary conditions, effectively antagonizing leukotriene activity.

Zafirlukast-D7 is a deuterated compound of Zafirlukast. Zafirlukast (T6736) has a CAS number of 107753-78-6. Zafirlukast (T6736) is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma.

CP-199331, a cysLT1 receptor antagonist, demonstrates equivalent potency to commercially available cysLT1 receptor antagonists zafirlukast and pranlukast. It shows favorable pharmacokinetic properties in both rats and monkeys, and unlike CP-85,958, no hepatotoxicity has been observed in monkeys.

CP-199330 is a cysteyl LT1 receptor antagonist with no hepatotoxicity and is equivalent to the commercially available CYSLT1 receptor antagonists Zafirlukast and Pranlukas.